Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of -77.33 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-06-30 was 8.00K shares, a 84.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-09-30 was 25.00K shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-06-30 was 50.00K shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was -77.33K shares, a 175.73% decline from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 102.12K shares, a 93.68% decline from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 1.62M shares.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 475.30K shares, a 921.71% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 98 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | -77.33K shares 10-K · filed 2026-03-04 | |||||
| 2024-12-31 | 102.12K shares 10-K · filed 2026-03-04 | -3.06M shares 10-K · filed 2025-03-13 | ||||
| 2023-12-31 | 1.62M shares 10-K · filed 2025-03-13 | |||||
| 2018-06-30 | 8.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | 8.00K shares 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | |||||
| 2017-09-30 | 25.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 75.00K shares derived: sum of 2 quarters · filed 2017-11-09 | 112.30K shares 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 87.30K shares 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | 37.30K shares 10-Q · filed 2017-05-11 | |||||
| 2016-12-31 | 475.30K shares 10-K · filed 2017-03-15 | |||||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-12 | -463.68K shares derived: sum of 2 quarters · filed 2017-03-15 | -463.68K shares derived: sum of 3 quarters · filed 2017-03-15 | -63.68K shares derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-12-31 | -463.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -463.68K shares derived: sum of 2 quarters · filed 2017-03-15 | -63.68K shares derived: sum of 3 quarters · filed 2017-03-15 | 46.52K shares 10-K · filed 2017-03-15 | ||
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 400.00K shares derived: sum of 2 quarters · filed 2015-11-12 | 510.20K shares 10-Q · filed 2015-11-12 | 502.23K shares derived: sum of 4 quarters · filed 2016-10-20 | ||
| 2015-06-30 | 400.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | 510.20K shares 10-Q · filed 2015-08-12 | 502.23K shares derived: sum of 3 quarters · filed 2016-10-20 | 502.23K shares derived: sum of 4 quarters · filed 2016-10-20 | ||
| 2015-03-31 | 110.20K shares 10-Q · filed 2015-05-20 | 102.23K shares derived: sum of 2 quarters · filed 2016-10-20 | 102.23K shares derived: sum of 3 quarters · filed 2016-10-20 | 122.23K shares derived: sum of 4 quarters · filed 2016-10-20 | ||
| 2014-12-31 | -7.97K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-10-20 | -7.97K shares derived: sum of 2 quarters · filed 2016-10-20 | 12.03K shares derived: sum of 3 quarters · filed 2016-10-20 | 12.03K shares 10-K/A · filed 2016-10-20 | 120.30K shares 10-K · filed 2015-03-24 | |
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-20 | 20.00K shares derived: sum of 2 quarters · filed 2015-05-20 | 20.00K shares 10-Q · filed 2015-05-20 | 204.28K shares derived: sum of 4 quarters · filed 2015-05-20 | ||
| 2014-06-30 | 20.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | 20.00K shares 10-Q · filed 2014-08-04 | 204.28K shares derived: sum of 3 quarters · filed 2015-05-20 | |||
| 2014-03-31 | 0.00 shares 10-Q · filed 2014-05-14 | 184.28K shares derived: sum of 2 quarters · filed 2015-05-20 | ||||
| 2013-12-31 | 184.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-20 | 344.28K shares 10-K · filed 2015-05-20 | 6.89M shares 10-K · filed 2014-03-19 | |||
| 2013-09-30 | 160.00K shares 10-Q · filed 2013-11-13 | |||||
| 2013-06-30 | 0.00 shares 10-Q · filed 2013-08-12 | 20.00K shares derived: sum of 2 quarters · filed 2013-08-12 | 1.95M shares derived: sum of 3 quarters · filed 2014-03-19 | 1.98M shares derived: sum of 4 quarters · filed 2014-03-19 | ||
| 2013-03-31 | 20.00K shares 10-Q · filed 2013-08-12 | 1.95M shares derived: sum of 2 quarters · filed 2014-03-19 | 1.98M shares derived: sum of 3 quarters · filed 2014-03-19 | 1.98M shares derived: sum of 4 quarters · filed 2014-03-19 | ||
| 2012-12-31 | 1.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-19 | 1.96M shares derived: sum of 2 quarters · filed 2014-03-19 | 1.96M shares derived: sum of 3 quarters · filed 2014-03-19 | 1.96M shares 10-K · filed 2014-03-19 | ||
| 2012-09-30 | 24.00K shares 10-Q · filed 2012-11-06 | 24.00K shares derived: sum of 2 quarters · filed 2012-11-06 | 24.00K shares 10-Q · filed 2012-11-06 | |||
| 2012-06-30 | 0.00 shares 10-Q · filed 2012-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2012-11-06 | ||||
| 2012-03-31 | 0.00 shares 10-Q · filed 2012-11-06 | |||||
| 2011-12-31 | 6.24M shares 10-K · filed 2014-03-19 | 5.23M shares 10-K · filed 2013-03-28 | ||||
| 2010-12-31 | 1.01M shares 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |